98%
921
2 minutes
20
BACKGROUND Myxopapillary ependymomas, a subtype of spinal ependymomas, are relatively rare in children and adolescents, primarily affecting the lower spinal region; however, they can also metastasize along the spinal axis, as well as intracranially. The clinical presentation typically involves signs and symptoms of conus medullaris or cauda equina dysfunction, including paralysis and sensory loss, accompanied by lower back pain. Ocular complications are not commonly seen in myxopapillary ependymomas. This case report emphasizes the need to consider spinal tumors in patients presenting with bilateral papilledema, particularly in the presence of neurological symptoms or increased cerebrospinal fluid protein levels. It also stresses the importance of spinal MRI to prevent misdiagnosis during ophthalmic assessments. CASE REPORT A 12-year-old boy, previously diagnosed with neuromyelitis optica at another hospital and initially responsive to intravenous methylprednisolone, returned with relapsed vision loss and neck and back pain. At Shenzhen Children's Hospital, an ophthalmological examination showed bilateral papilledema with poorly defined margins. Due to his neurological symptoms, a consultation was conducted, revealing several positive signs. A lumbar puncture indicated elevated cerebrospinal fluid pressure and protein levels. A subsequent spinal MRI identified a space-occupying lesion in the spinal column. The patient underwent neurosurgical intervention to remove the intradural lesion, and the pathology confirmed a WHO Grade 2 myxopapillary ependymoma. Postoperatively, his right eye vision improved to 20/40, and his left eye vision to 20/20, resolving his diplopia and restoring normal muscle strength and tone in all limbs. However, a tumor recurrence 3 months later necessitated a second surgery. CONCLUSIONS Ocular complications are rare in pediatric patients with myxopapillary ependymoma. Timely recognition of associated symptoms by ophthalmologists, followed by a comprehensive neurological evaluation to uncover potential neurologic issues, can significantly improve outcomes through early intervention for myxopapillary ependymoma.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932546 | PMC |
http://dx.doi.org/10.12659/AJCR.946269 | DOI Listing |
J Pathol Transl Med
September 2025
Department of Pathology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.
Central nervous system tumors with BCL6 corepressor (BCOR) internal tandem duplications (ITDs) constitute a rare, recently characterized pediatric neoplasm with distinct molecular and histopathological features. To date, 69 cases have been documented in the literature, including our institutional case. These neoplasms predominantly occur in young children, with the cerebellum representing the most frequent anatomical location.
View Article and Find Full Text PDFCureus
August 2025
Spine Surgery, National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez", Mexico City, MEX.
Background Spinal ependymomas are the most common intradural tumors in adults and frequently lead to progressive neurological decline due to spinal cord compression. They typically present with subacute symptoms. The 2016 WHO classification stratifies them by histological grade, with recent updates incorporating molecular features.
View Article and Find Full Text PDFBrain Pathol
August 2025
Department of Pathology, Massachusetts General Hospital, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
The Consortium to Inform Molecular and Practical Approaches to Central Nervous System Tumor Taxonomy (cIMPACT-NOW) updates provide guidelines for the diagnosis of central nervous system (CNS) tumors and suggestions for future World Health Organization (WHO) classification. Following publication of the fifth edition WHO Classification of CNS Tumors (WHO CNS5) in 2021, the cIMPACT-NOW working group "Clarification" reviewed WHO CNS5 and prioritized two topics for further elucidation: (a) distinction of Glioblastoma, IDH-wildtype from Diffuse pediatric-type high-grade glioma, H3-wildtype, and IDH-wildtype and (b) clarification of subgroups of posterior fossa (PF) ependymal tumors. Recommendations regarding the IDH- and H3-wildtype diffuse high-grade gliomas include: (1) use caution assigning CNS WHO grade 4 (diagnosis of Glioblastoma, IDH-wildtype) to a "TERT promoter only", histologically low-grade, IDH-wildtype tumor; (2) EGFR gene amplification and +7/-10 chromosome copy number alterations should not be used as solitary defining features for diagnosing high-grade gliomas as Glioblastoma, IDH-wildtype in patients <40 years of age; (3) Diffuse pediatric-type high-grade glioma, H3-wildtype, and IDH-wildtype should be considered in the differential diagnosis in adults, especially those <40 years of age; (4) PDGFRA alteration, EGFR alteration, or MYCN amplification count as key molecular features of Diffuse pediatric-type high-grade glioma, H3-wildtype, and IDH-wildtype only in patients <25 years.
View Article and Find Full Text PDFChilds Nerv Syst
August 2025
Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Objective: This study aims to understand the impact of the COVID-19 pandemic on the diagnosis, management, and clinical outcomes of children and young people (CYP) with brain tumours in England.
Design: UK-based retrospective observational study with two components. Nationwide brain tumour incidence data from the National Disease Registration Service was obtained (2015-2020) to study trends in newly diagnosed cases.
Med Sci (Basel)
August 2025
Department of Neurology, Faculty of Medicine, Cairo University, Cairo 12613, Egypt.
Background: Ependymomas are primary CNS neoplasms that arise from the ependymal cells of the brain and spinal cord, accounting for 3-6% of all CNS tumors.
Aims: This study provides a comprehensive analysis of ependymoma survival patterns and examines non-cancer causes of death in the US.
Methods: This retrospective study used data from SEER 17 registries between 2000 and 2019 to evaluate the incidence of ependymoma, as well as the survival and mortality trends in the US.